阿尔茨海默病患者脑脊液可溶性血小板衍生生长因子受体β与认知损害及脑脊液生物标志物的相关性研究  

Correlation between cerebrospinal fluid soluble platelet-derived growth factor receptorβand cognitive damage and cerebrospinal fluid core biological markers in Alzheimer′s disease

作　　者：王慧敏 汤其强 Wang Huimin;Tang Qiqiang(Department of Neurology,Provincial Hospital Affiliated to Anhui Medical University,Hefei 230001,China)

机构地区：[1]安徽医科大学附属省立医院神经内科,合肥230001

出　　处：《中华神经科杂志》2022年第1期47-52,共6页Chinese Journal of Neurology

摘　　要：目的研究阿尔茨海默病(AD)患者脑脊液可溶性血小板衍生生长因子受体β(sPDGFRβ)浓度与认知损害程度及脑脊液生物标志物的相关性。方法选取2018年9月至2020年8月安徽医科大学附属省立医院神经内科收治的AD患者(AD组)50例,及同期住院的认知功能正常的对照组33例,对其完善神经心理学测评,依据临床痴呆量表(CDR)评分将AD患者分为轻度AD组和中重度AD组,比较3组的临床资料、认知功能。采用酶联免疫吸附法测定各组患者的脑脊液sPDGFRβ、脑脊液β-淀粉样蛋白(Aβ)1-42、脑脊液Aβ1-40、总tau蛋白(T-tau)及磷酸化tau蛋白(P-tau)含量,比较3组间差异。将AD组根据载脂蛋白E(ApoE)基因是否携带ε4基因分为ApoE4+组和ApoE4-组,比较组间脑脊液sPDGFRβ差异。并将轻度AD组和中重度AD组、对照组脑脊液sPDGFRβ与认知损害程度和脑脊液Aβ1-42、T-tau及P-tau含量进行相关分析。结果中重度AD组脑脊液sPDGFRβ浓度[(235.358±86.187)pg/ml]和轻度AD组脑脊液sPDGFRβ浓度[(219.301±69.711)pg/ml]高于对照组[(184.878±52.944)pg/ml],差异有统计学意义(F=3.90,P=0.024)。而在AD患者中,ApoE4+组脑脊液sPDGFRβ[(219.493±76.745)pg/ml]和ApoE4-组[(222.802±81.665)pg/ml]间差异无统计学意义(t=-0.13,P=0.900)。相关分析结果显示,轻度AD组脑脊液sPDGFRβ与脑脊液P-tau水平呈正相关(r=0.43,P=0.019),与Aβ1-42、T-tau水平、简易精神状态检查量表评分及蒙特利尔认知评估量表评分无相关性,而在中重度AD组和对照组中则均无相关性。结论脑脊液sPDGFRβ在AD患者中升高,并在早期与P-tau有关;周细胞损伤可能参与了AD患者脑内tau蛋白的磷酸化。Objective To investigate the relationship between the concentration of soluble platelet-derived growth factor receptorβ(sPDGFRβ)in the cerebrospinal fluid(CSF)of patients with Alzheimer′s disease(AD)and the degree of cognitive impairment and cerebrospinal fluid biomarkers.Methods A total of 50 patients with AD in the Department of Neurology of Provincial Hospital Affiliated to Anhui Medical University from September 2018 to August 2020 were selected as AD group,and 33 patients with normal cognition who had no significant difference in age and gender in the same period served as control group.The neuropsychological evaluation was conducted.According to the Clinical Dementia Rating scale scores,the AD patients were divided into mild AD group and moderate to severe AD group.The clinical data and cognitive function of the three groups were compared.And the level of CSF sPDGFRβ,CSF amyloid-β(Aβ)1-40,CSF Aβ1-42,CSF total tau protein(T-tau),CSF phosphorylated tau protein(P-tau)were measured by enzyme linked immunosorbent assay in each group.According to whether apolipoprotein E4(ApoE4)gene was carried,the patients with AD were divided into ApoE4+group and ApoE4-group.Differences among the three groups were compared and the correlation analysis was carried out.Results The levels of sPDGFRβin the CSF of the mild AD group[(219.301±69.711)pg/ml]and the moderate to severe AD group[(235.358±86.187)pg/ml]were significantly higher than that of the control group[(184.878±52.944)pg/ml,F=3.90,P=0.024],while there was no significant difference in the level of CSF sPDGFRβbetween the ApoE4+group[(219.493±76.745)pg/ml]and the ApoE4-group[(222.802±81.665)pg/ml,t=-0.13,P=0.900].And the level of sPDGFRβin the CSF in the mild AD group was positively correlated with the level of CSF P-tau(r=0.43,P=0.019),but not correlated with Aβ1-42,T-tau,Mini-Mental State Examination scores or Montreal Cognitive Assessment scores,whereas no significant correlation was found in the control group and the moderate to severe AD group.Conclu

关 键 词：阿尔茨海默病 可溶性血小板衍生生长因子受体β 周细胞 认知功能 脑脊液生物标志物 

分 类 号：R749.16[医药卫生—神经病学与精神病学]